Cardinal Health, Inc. CAH

NYSE · Healthcare · Medical - Distribution

$272.81

Close on Fri, 20 Nov 2026 · market value $63.1B

What the price is betting on

Below its record

At $273, the price assumes revenue shrinks about 7.2% a year for five years, from $258B to about $181B by FY2031. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes−7.2%
Analysts, next two years5.3%
Last 3 years7.3%

Revenue growth a year. The price figure comes from a reverse DCF at a 7.4% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than CAH? Check up to 5 of your stocks at once, free, no account.

0$100B$200B$300B$400B$258B'23'24'25'26Sep '26'27'28'29'30'31What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$487

Base

$547

Bull

$615

Today $273

  • Bear $487. Cash flow grows 3% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $547. Cash flow grows 5% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $615. Cash flow grows 7% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2027$244B$266B, on the path
  3. FY2028$226B$282B, on the path
  4. FY2029$210B$297B, on the path
  5. FY2030$195B$307B, on the path
  6. FY2031$181B$315B, on the path

Each year's revenue at −7.2% growth from $258B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Distribution · listed on NYSE

Revenue, FY2026
$254B
Growth, 3 years a year
7.3%
Cash margin
1.8%
Net debt
$5.1B
Shares, 3-year change
−9.5%
Dividend yield
0.8%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.